|
| Tuesday, December 18, 2018 |
|
|
Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform |
| Bristol-Myers Squibb Company, Eisai Co., Ltd. and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine, Inc. has announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3's RNA splicing platform can provide a more powerful response against cancer. more info >> |
|
| Monday, December 17, 2018 |
|
|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma |
| Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil. more info >> |
|
| Wednesday, December 12, 2018 |
|
|
GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics |
| The Global Antibiotic Research and Development Partnership (GARDP), Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited have signed an agreement for GARDP to access and screen components of Eisai and Takeda's chemical libraries. more info >> |
|
| Thursday, December 6, 2018 |
|
|
Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research |
| Eisai Co., Ltd. and University College London (UCL) announced today that they have commenced preparations for Phase I clinical studies on E2814, the first clinical candidate from their drug discovery collaboration, in Alzheimer's disease patients within fiscal 2018. more info >> |
|
| Thursday, November 29, 2018 |
|
|
Eisai: MOVICOL Launched in Japan |
| MOVICOL is the first polyethylene glycol preparation indicated for treatment of chronic constipation in Japan, available for adults and children 2 years of age and older. more info >> |
|
| Wednesday, November 28, 2018 |
|
|
Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa |
| Eisai Co., Ltd. announced today that based on topline results, the primary efficacy endpoint was met in a Phase III clinical study (Study 342) conducted for submission in Japan, which evaluated its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) as monotherapy for partial-onset seizures. more info >> |
|
| Tuesday, November 27, 2018 |
|
|
Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium |
| Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS). more info >> |
|
| Friday, November 23, 2018 |
|
|
Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting |
| Eisai Co., Ltd. announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 72nd American Epilepsy Society Annual Meeting (AES 2018) to be held from November 30 to December 4, 2018 in New Orleans in the United States. more info >> |
|
| Wednesday, November 14, 2018 |
|
|
Eisai Receives "IR Grand Prix Award" |
| Eisai Co., Ltd. has announced that it received the "IR Grand Prix Award" at the IR Award 2018 held by the Japan Investor Relations Association (JIRA). more info >> |
|
| Monday, November 12, 2018 |
|
|
Eisai Launches Lenvima (Lenvatinib) in China |
| Eisai Co., Ltd. announced that its Chinese subsidiary Eisai China Inc. (ECI) has launched the kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in China. more info >> |
|
|
|
